Navigate Fool.com
Will PCYC beat
the market?



Community Rating: 2 Stars: Unattractive

90.04 -1.82 (-1.98%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $92.42
Previous Close $91.86
Daily Range $88.70 - $94.36
52-Week Range $72.58 - $154.89
Market Cap $6.7B
P/E Ratio 105.59
Dividend (Yield) $0.00 (0.0%)
Volume 1,493,569
Average Daily Volume 1,571,401
Current FY EPS -$0.49

How do you think PCYC
will perform against the market?

Top PCYC Bull/Bear Pitches


alaskiian (2.96)
Submitted February 12, 2010

Well....back in 2000 hit 80.00....undervalued...4star watch...i'm in!!!

0 Replies Reply Report this Post

colddrink73 (< 20)
Submitted November 30, 2011

ok ok so here is the truth.<br />This company is losing money and will continue to loose money untill it's products gain FDA approval. There are 2 problems with this. The main problem is they may neve … More

3 Replies Reply Report this Post

News & Commentary

Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics

Takeda, Eli Lilly, Immunomedics, and Pharmacyclics could loom large in health care headlines this Tuesday morning.

Mid-Afternoon Market Update: Markets Continue to Take a Beating as Rite Aid Moves Higher

Mid-Day Market Update: Rite Aid Shares Gain On Upbeat Earnings; Imperva Drops

Tuesday's ETF Movers: BBH, IDU

Credit Suisse Sees These Six Stocks as Momentum Traps

Is It Time to Buy These 2 Cancer-Fighting Companies?

Seattle Genetics' (SGEN) and Pharmacyclics' (PCYC) shares are tumbling, despite promising cancer drugs that could see significant sales growth.

Morgan Stanley Starts Mixed Coverage on Top Biotech Stocks

PCYC Makes Notable Cross Below Critical Moving Average

The Growth Driver Johnson & Johnson Investors Need to Watch

A slate of recent wins suggest Johnson's (JNJ) pharmaceutical division remains one of the best in the business.

Weekly Insider Sells Highlight: BX, PCYC, MAS, ITMN

See More PCYC News...






A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks